01 Identity and provenance
- Accepted binomial
- Swertia chirayita
- Common names
- Chirata
- Family (APG IV)
- Gentianaceae
- Part used
- Whole plant
- Verification tier
- Tier 2 · Verified Clinical columns reviewed and a source is on record.
- Reviewer note (2026 audit)
- CORRECTED - F:M: Chemical class cell duplicated the plant part; every field from composition onward sat one column right of its header
Reference not supplied - claim unverified against primary literature.
02 Constituent chemistry
| Chemical class | Marker compound | Synthetic analogue in use |
|---|---|---|
| Amarogentin, Swertiamarin, Mangiferin, Xanthones | Amarogentin
Whole plant
|
Metformin (similar antidiabetic property |
The analogue column is what makes the interaction reasoning tractable: where a constituent has a marketed structural counterpart, the counterpart's interaction profile is the starting hypothesis for the plant.
03 Stated application
- Reported activity
- Antidiabetic, Bitter tonic
- Marketed in
- Chirayata Churna, Diabecon
- Reported adverse effects
- Stomach irritation, Nausea, Hypoglycemia (with antidiabetic drugs
04 Interaction matrix
Source column, verbatim: Antidiabetic drugs, Antihypertensive drugs
Normalised onto 2 canonical drug classes below.
Curated from the reviewed source
| Drug class | Severity | Mechanism type | Provenance | Expected effect | |
|---|---|---|---|---|---|
|
Antidiabetic drugs (insulin, sulfonylureas, biguanides, GLP-1, SGLT2)
Endocrine
|
3Major | PD-additive | curated B | Symptomatic hypoglycaemia, sweating, tremor, confusion; severe events rep… | why ▾ |
Class mechanism. Hypoglycaemic botanicals act through insulin secretagogue, insulin-sensitising, alpha-glucosidase-inhibiting or glucose-transport routes. Added to a titrated pharmacological regimen the effects summate rather than plateau.
| |||||
|
Antihypertensives
Cardiovascular
|
2Moderate | PD-additive | curated B | Orthostatic hypotension, dizziness, syncope and falls; or loss of blood-p… | why ▾ |
Class mechanism. Vasodilator, diuretic, ACE-inhibitory and calcium-antagonist activity in botanical extracts adds to prescribed blood-pressure lowering. A minority (ephedrine-, glycyrrhizin- and caffeine-bearing) act in the opposite direction and antagonise control.
| |||||
05 Hazard register
The audit recorded no hazard beyond the interaction profile. The controlled-vocabulary field reads not assessed, which means the assessment has not been done rather than that it came back clear.
06 Confusable material
No same-genus or shared-common-name entry in the corpus.
07 Mechanism map
Chemistry sorts to the left, pharmacology to the right. Dashed edges are predicted. Drag nodes, scroll to zoom, export at 3× for a figure.
08 Open literature
Abstract-scoped query built from this binomial, its common names and its marker compounds, run live against Europe PMC, PubMed and OpenAlex, then ranked locally against an evidence hierarchy.
09 Isomechanistic neighbours
Species whose interaction profile overlaps this one, ranked by shared severity weight rather than by count — a shared contraindication counts for more than a shared minor signal. Practical use: these are the plants you should not stack with this one, because the mechanisms summate.
| Species | Family | Shared classes | Weight | Jaccard |
|---|---|---|---|---|
| Azadirachta indica
Neem |
Meliaceae | 2 | 0.67 | |
| Allium sativum
Garlic |
Amaryllidaceae | 2 | 0.50 | |
| Aegle marmelos
Bael |
Rutaceae | 2 | 0.40 | |
| Tinospora cordifolia
Guduchi |
Menispermaceae | 2 | 0.50 | |
| Cinnamomum verum
Cinnamon |
Lauraceae | 2 | 0.67 | |
| Calendula officinalis
Calendula |
Asteraceae | 2 | 0.67 |
10 References and notes
No citation is on record for this entry. That is itself the finding: the audit flagged it, and it is why the entry does not carry an A evidence grade.
Curator notes
No notes yet.
Sign in to add notes and save monographs.